Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGEN NASDAQ:ATHA NASDAQ:ORTX OTCMKTS:OSIR NASDAQ:TARS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGENAgenus$4.42$4.32$1.38▼$7.34$140.84M1.43745,507 shs244,866 shsATHAAthira Pharma$4.06+10.5%$3.92$2.20▼$8.26$15.98M3.0134,683 shs69,852 shsORTXOrchard Therapeutics$16.70$16.59$4.24▼$16.72$380.09M0.55157,287 shsN/AOSIROsiris Therapeutics$18.99$18.99$7.01▼$19.30$655.69MN/A205,753 shsN/ATARSTarsus Pharmaceuticals$71.15-0.1%$59.15$36.07▼$76.81$3.00B0.81662,961 shs115,511 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGENAgenus+13.92%+9.14%+0.91%-27.78%-4.33%ATHAAthira Pharma+1.38%-1.87%-5.17%-21.45%-22.33%ORTXOrchard Therapeutics0.00%0.00%0.00%0.00%0.00%OSIROsiris Therapeutics0.00%0.00%0.00%0.00%0.00%TARSTarsus Pharmaceuticals-2.39%+1.21%+29.44%+68.14%+94.40%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGENAgenus$4.42$4.32$1.38▼$7.34$140.84M1.43745,507 shs244,866 shsATHAAthira Pharma$4.06+10.5%$3.92$2.20▼$8.26$15.98M3.0134,683 shs69,852 shsORTXOrchard Therapeutics$16.70$16.59$4.24▼$16.72$380.09M0.55157,287 shsN/AOSIROsiris Therapeutics$18.99$18.99$7.01▼$19.30$655.69MN/A205,753 shsN/ATARSTarsus Pharmaceuticals$71.15-0.1%$59.15$36.07▼$76.81$3.00B0.81662,961 shs115,511 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGENAgenus+13.92%+9.14%+0.91%-27.78%-4.33%ATHAAthira Pharma+1.38%-1.87%-5.17%-21.45%-22.33%ORTXOrchard Therapeutics0.00%0.00%0.00%0.00%0.00%OSIROsiris Therapeutics0.00%0.00%0.00%0.00%0.00%TARSTarsus Pharmaceuticals-2.39%+1.21%+29.44%+68.14%+94.40%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGENAgenus 2.20Hold$14.50228.05% UpsideATHAAthira Pharma 1.00Sell$4.00-1.36% DownsideORTXOrchard Therapeutics 0.00N/AN/AN/AOSIROsiris Therapeutics 0.00N/AN/AN/ATARSTarsus Pharmaceuticals 2.50Moderate Buy$69.33-2.55% DownsideCurrent Analyst Ratings BreakdownLatest ATHA, TARS, AGEN, OSIR, and ORTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/20/2025AGENAgenusHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy10/20/2025TARSTarsus PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$72.00 ➝ $88.0010/20/2025TARSTarsus PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$72.00 ➝ $88.0010/8/2025AGENAgenusWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025ATHAAthira PharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025TARSTarsus PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025AGENAgenusWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025ATHAAthira PharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025TARSTarsus PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/19/2025ATHAAthira PharmaMizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$4.009/10/2025AGENAgenusHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$23.00(Data available from 10/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGENAgenus$101.71M1.38N/AN/A($13.06) per share-0.34ATHAAthira PharmaN/AN/AN/AN/A$11.60 per shareN/AORTXOrchard Therapeutics$22.66M16.77N/AN/A$7.74 per share2.16OSIROsiris TherapeuticsN/AN/AN/AN/AN/AN/ATARSTarsus Pharmaceuticals$182.95M16.42N/AN/A$5.87 per share12.12Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGENAgenus-$227.21M-$7.15N/AN/AN/A-167.52%N/A-81.04%11/11/2025 (Estimated)ATHAAthira Pharma-$96.94M-$15.50N/AN/AN/AN/A-139.40%-106.84%11/6/2025 (Estimated)ORTXOrchard Therapeutics-$150.66M-$0.94N/AN/AN/A-333.90%-74.94%-33.51%N/AOSIROsiris TherapeuticsN/AN/A0.00∞N/AN/AN/AN/AN/ATARSTarsus Pharmaceuticals-$115.55M-$2.33N/AN/AN/A-31.13%-32.36%-21.04%11/12/2025 (Estimated)Latest ATHA, TARS, AGEN, OSIR, and ORTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/12/2025Q3 2025TARSTarsus Pharmaceuticals-$0.35N/AN/AN/A$114.22 millionN/A11/11/2025Q3 2025AGENAgenus$2.63N/AN/AN/A$80.39 millionN/A11/6/2025Q3 2025ATHAAthira Pharma-$0.17N/AN/AN/AN/AN/A8/11/2025Q2 2025AGENAgenus-$0.78-$1.00-$0.22-$1.00$49.71 million$25.70 million8/7/2025Q2 2025ATHAAthira Pharma-$1.80-$1.80N/A-$0.18N/AN/A8/6/2025Q2 2025TARSTarsus Pharmaceuticals-$0.33-$0.48-$0.15-$0.48$95.81 million$102.66 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGENAgenusN/AN/AN/AN/AN/AATHAAthira PharmaN/AN/AN/AN/AN/AORTXOrchard TherapeuticsN/AN/AN/AN/AN/AOSIROsiris TherapeuticsN/AN/AN/AN/AN/ATARSTarsus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGENAgenusN/A0.060.06ATHAAthira PharmaN/A10.8110.81ORTXOrchard Therapeutics0.203.122.98OSIROsiris TherapeuticsN/AN/AN/ATARSTarsus Pharmaceuticals0.225.265.21Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGENAgenus61.46%ATHAAthira Pharma57.12%ORTXOrchard Therapeutics29.90%OSIROsiris Therapeutics0.28%TARSTarsus Pharmaceuticals90.01%Insider OwnershipCompanyInsider OwnershipAGENAgenus5.50%ATHAAthira Pharma19.80%ORTXOrchard Therapeutics2.91%OSIROsiris Therapeutics43.40%TARSTarsus Pharmaceuticals8.97%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGENAgenus44031.86 million30.11 millionOptionableATHAAthira Pharma403.94 million3.16 millionOptionableORTXOrchard Therapeutics16622.76 million22.10 millionOptionableOSIROsiris Therapeutics34234.53 millionN/ANot OptionableTARSTarsus Pharmaceuticals5042.21 million38.43 millionOptionableATHA, TARS, AGEN, OSIR, and ORTX HeadlinesRecent News About These CompaniesAllspring Global Investments Holdings LLC Sells 36,159 Shares of Tarsus Pharmaceuticals, Inc. $TARSOctober 21 at 3:24 AM | marketbeat.comHC Wainwright & Co. Maintains Tarsus Pharmaceuticals (TARS) Buy RecommendationOctober 21 at 2:34 AM | msn.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Recommendation of "Moderate Buy" by AnalystsOctober 20 at 2:37 AM | marketbeat.comTarsus Pharmaceuticals, Inc. $TARS Shares Purchased by Aberdeen Group plcOctober 18 at 3:34 AM | marketbeat.comTarsus Pharmaceuticals (NASDAQ:TARS) Hits New 12-Month High - Time to Buy?October 13, 2025 | marketbeat.comWhy Tarsus Pharmaceuticals (TARS) Is Up 21.6% After Xdemvy’s Uptake and New Trial Announcements—And What's NextOctober 9, 2025 | finance.yahoo.comWeiss Ratings Reaffirms "Sell (D-)" Rating for Tarsus Pharmaceuticals (NASDAQ:TARS)October 9, 2025 | marketbeat.comTarsus Pharmaceuticals (NASDAQ:TARS) Reaches New 52-Week High - What's Next?October 6, 2025 | marketbeat.comTarsus Pharmaceuticals (TARS) Moves 10.9% Higher: Will This Strength Last?October 6, 2025 | zacks.comTarsus Pharmaceuticals (NASDAQ:TARS) Trading 9.6% Higher - Time to Buy?October 3, 2025 | marketbeat.comTarsus Pharmaceuticals (NASDAQ:TARS) Sets New 12-Month High - Should You Buy?September 30, 2025 | marketbeat.comTarsus Pharmaceuticals (NASDAQ:TARS) CEO Sells $332,220.00 in StockSeptember 27, 2025 | insidertrades.comBobak Azamian Sells 6,000 Shares of Tarsus Pharmaceuticals (NASDAQ:TARS) StockSeptember 26, 2025 | marketbeat.comTarsus Pharmaceuticals: Considering If The Big Marketing Push Will Pay OffSeptember 26, 2025 | seekingalpha.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Average Recommendation of "Moderate Buy" by AnalystsSeptember 25, 2025 | marketbeat.com5,600 Shares in Tarsus Pharmaceuticals, Inc. $TARS Purchased by Strs OhioSeptember 24, 2025 | marketbeat.comAssenagon Asset Management S.A. Trims Position in Tarsus Pharmaceuticals, Inc. $TARSSeptember 22, 2025 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Harrow Health (HROW) and IDEAYA Biosciences (IDYA)September 10, 2025 | theglobeandmail.comTarsus to Participate in Upcoming Investor ConferencesAugust 27, 2025 | globenewswire.com3 Biotech Catalysts Present Major Opportunity (TARS)...August 25, 2025 | marketbeat.comLyme Disease Is Spiking. This Biotech Nears A Treatment And A Buy Point.August 15, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025Why Datavault May Be the Penny AI Stock Investors Have Waited ForBy Nathan Reiff | September 22, 2025Salesforce’s Long-Awaited Inflection is Here: Rally On!By Thomas Hughes | October 16, 2025How Berkshire's OxyChem Buy Cements Its Long-Term StrengthBy Jeffrey Neal Johnson | October 2, 2025Meta vs OpenAI: Is Sora a True Threat to Meta's Dominance?By Leo Miller | October 20, 2025ATHA, TARS, AGEN, OSIR, and ORTX Company DescriptionsAgenus NASDAQ:AGEN$4.42 0.00 (0.00%) As of 12:42 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.Athira Pharma NASDAQ:ATHA$4.06 +0.39 (+10.49%) As of 12:42 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.Orchard Therapeutics NASDAQ:ORTXOrchard Therapeutics, a Kyowa Kirin company, is a global gene therapy leader focused on ending the devastation caused by genetic and other severe diseases by discovering, developing, and commercializing new treatments that tap into the curative potential of hematopoietic stem cell (HSC) gene therapy. In this approach, a patient’s own blood stem cells are genetically modified outside of the body and then reinserted, with the goal of correcting the underlying cause of disease with a single treatment. Founded in 2015, Orchard’s roots go back to some of the first research and clinical developments involving HSC gene therapy. Our team has played a central role in the evolution of this technology from a promising scientific idea to a potentially life-transforming reality. Today, Orchard is advancing a pipeline of HSC gene therapies designed to address serious diseases where the burden is immense for patients, families and society and current treatment options are limited or do not exist.Osiris Therapeutics OTCMKTS:OSIR$18.99 0.00 (0.00%) As of 04/17/2019Osiris Therapeutics, Inc. researches, develops, manufactures, markets, and distributes regenerative medicine products in the United States. Its products include Grafix and Stravix for treating chronic wounds of diabetic foot ulcers, venous leg ulcers, pressure ulcers, arterial ulcers, and severe burns, as well as surgical and trauma wounds; BIO4 for bone repair and regeneration in spine, trauma, extremity, cranial, and foot and ankle surgeries; and Cartiform for treating articular cartilage lesions in the knee and other joints. The company also develops and markets Menvivo for the repair of meniscus; and TruSkin for treating chronic wounds. It markets and distributes its products directly to physicians, hospitals, and other healthcare providers, as well as through agents and distributors. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.Tarsus Pharmaceuticals NASDAQ:TARS$71.15 -0.04 (-0.06%) As of 12:42 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Will D-Wave's European Expansion Keep Fueling the Rally? Navitas Soars 78% on NVIDIA Update: Is This Rally Sustainable? Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet Waymo’s Global Expansion Strengthens the Case for GOOGL Stock Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Meta vs OpenAI: Is Sora a True Threat to Meta's Dominance? Institutions Are Fueling CrowdStrike’s Next Leg Higher This AI Chip Giant Could Be the Market’s Next Big Winner Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
